Acacia Pharma Group Plc
Acacia Pharma Group Plc
  • Products
    • Overview
    • Therapeutic Areas
    • Marketed Products
    • APD403
  • Media
    • Press Releases
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholder Meetings
    • California Compliance statement
    • Contact
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map
Acacia Pharma Group Plc
  • Products
    • Overview
    • Therapeutic Areas
    • Marketed Products
    • APD403
  • Media
    • Press Releases
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholder Meetings
    • California Compliance statement
    • Contact
  • Contact

Transforming medicine

Advancing care

Home > Investors > Shareholder Meetings

Investors > Shareholder Meetings

Recommended Acquisition by Eagle – Scheme Document

Recommended Acquisition by Eagle – Proxy Forms

Recommended Acquisition by Eagle – Virtual Meeting Guide, and

Recommended Acquisition by Eagle – S.311A Statement

Investors

  • Overview
  • Regulatory announcements
  • Shareholder Meetings
  • California Compliance Statement
  • Contact
Acacia Pharma Group Plc
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map

© 2025 Acacia Pharma Group Plc

(Registered in England and Wales No: 09759376)
Registered office address: The Officers’ Mess, Royston Road, Duxford, Cambridge CB22 4QH, UK

Acacia Pharma Limited (Registered in England and Wales No: 05934843) and Acacia Pharma Inc (Incorporated under the laws of Delaware, No: 5799660) are members of the Acacia Pharma Group

Website by Instinctif Partners

By continuing to use acaciapharma.com you will be agreeing to the website Terms & Conditions, the Privacy Policy, and the use of Cookies.

By continuing to use acaciapharma.com you will be agreeing to the website Terms & Conditions, the Privacy Policy, and the use of Cookies.